India, May 6 -- British drug major AstraZeneca Plc. (AZN.L,AZN) announced Tuesday that the European Union or EU has approved Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma or MCL who are not eligible for autologous stem cell transplant.
MCL is a rare and typically aggressive form of non-Hodgkin lymphoma, often diagnosed at an advanced stage.
The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use or CHMP. It is the first and only BTK inhibitor approved in this indication in the EU, the company noted.
The approval follows the recent approval for Calquence monotherap...